Incyte Corp (NASDAQ:INCY)

CAPS Rating: 2 out of 5

The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar TerryHoodSr (49.23) Submitted: 4/15/2014 9:52:51 AM : Outperform Start Price: $43.85 INCY Score: +1.51

trade buy@ 44 TP 60

Recs

0
Member Avatar TMFTycoon (< 20) Submitted: 3/20/2014 4:06:59 PM : Underperform Start Price: $63.48 INCY Score: +28.37

I think Incyte needs a secondary source of revenue besides its main drug, Jakafi, and in the meantime, shares have run up based on Jakafi's success.

Recs

0
Member Avatar TerryFool (22.07) Submitted: 3/11/2014 8:25:41 AM : Outperform Start Price: $49.92 INCY Score: -11.07

TP 73 EPS 1YR 64% 2YR 140% 5YR 80%

Recs

0
Member Avatar 1russianguy (62.23) Submitted: 2/4/2014 12:14:09 PM : Outperform Start Price: $62.99 INCY Score: -34.75

Bill Gunderson long.

Recs

0
Member Avatar atlas1701 (28.13) Submitted: 1/19/2014 10:18:31 PM : Outperform Start Price: $63.24 INCY Score: -29.72

Incyte has a lot of promise. They have molecules that are been dev for rare unmet diseases.
http://www.incyte.com/research/pipeline

I call this a strong buy today because of the Jak 1/2 targets. They have the mylo drug approved and doing well and this target (Jak ) will have a lot of activity in diff diseases. They are a growing co. If they hit on even a third of their pipeline we should see the mkt cap double

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 5/24/2013 8:27:07 AM : Outperform Start Price: $22.14 INCY Score: +90.29

Incyte's share price seems to have stagnated while the fortunes of mid-cap biopharma peers such as Regeneron, Alkermes, and Aegerion have improved dramatically amidst a furor of enthusiasm for the sector. Nevertheless, I recently read the transcript of the Q1 earnings call and I don't see anything to be pessimistic about. Incyte still operates at a significant loss but Jakafi/Jakavi revenues are rising in line with expectations and a 60M milestone payment from Novartis related to Jakavi will likely be forthcoming in the near future. Meanwhile, I'm optimnistic about the success of the RESPONSE trial for Jakafi in polycythemia vera. There are numerous other pipeline compounds in late stage development with big pharma partners.

Recs

1
Member Avatar bclear2 (< 20) Submitted: 5/8/2013 2:25:20 AM : Outperform Start Price: $21.71 INCY Score: +92.90

promising JAK inhibitors with big potential in treating various cancers and inflammatory diseases such as rheumatoid arthritis and psoriasis.

Recs

0
Member Avatar ayuddha (24.88) Submitted: 7/15/2012 5:18:50 PM : Outperform Start Price: $25.50 INCY Score: +39.11

It was picked by www.hechtsoft.de Trade Alerts.

Recs

0
Member Avatar p1a5244 (77.07) Submitted: 9/18/2011 11:15:17 PM : Outperform Start Price: $14.35 INCY Score: +158.25

9/18/11 Options Predictor Rank #12. P/C Ratio 0.015 and Call Sizzle 4.756.

Recs

0
Member Avatar thl101 (< 20) Submitted: 7/9/2011 10:57:24 AM : Outperform Start Price: $19.57 INCY Score: +89.94

Incyte is entering a critical phase of its transition from a biotech into a pharmaceutical. Having made strategic alliances with big pharma, it has reduced its developmental liabilities while maintaining control of its primary drugs in the US market. As the indications its drugs are targeting have few to no current effective therapies, Incyte will be positioned to gain market share rapidly and expand earnings quickly.

Recs

0
Member Avatar oncqueen (73.69) Submitted: 6/6/2011 10:13:02 AM : Outperform Start Price: $17.09 INCY Score: +119.96

This is a "first-to-the-table" drug for a class of disorders for which current treament is a hassle (periodic large volume bloodletting) or can cause other significant problems (making other blood counts worse, with a risk of bleeding and infection).

Recs

0
Member Avatar jmad0 (< 20) Submitted: 2/4/2011 3:29:47 AM : Outperform Start Price: $14.86 INCY Score: +160.95

I have owned and watched INCY since Oct. 2008 and still think it is a nifty little company with plenty of potential to do good. Maybe it's because I have an orphan disease ... hey, "buy what you know."

Recs

0
Member Avatar 5starman (< 20) Submitted: 9/15/2010 7:53:46 PM : Outperform Start Price: $14.20 INCY Score: +152.15

New drug for rare blood cancer.

Recs

1
Member Avatar Cosmo21 (< 20) Submitted: 6/7/2010 5:04:58 PM : Outperform Start Price: $12.03 INCY Score: +198.24

If you saw the news out by the fool today on INCY you would realize they really are foolish. What kind of idiot recycles a story from march and trashes a company is doing all the right things, unless they are short! Do your own homework and you find a great pipeline, collaberations with big pharma and a well develpoed r&amp;d.
<br />&lt;br /&gt;Don't be fooled, get long!

Recs

1
Member Avatar markymark69 (< 20) Submitted: 3/23/2010 3:42:55 PM : Outperform Start Price: $14.16 INCY Score: +159.66

I bought into this stock on 03/05/2010 @ $11.53. So far its one my best performing stocks. My wife works for a CRO (not involved with any INCY's studies) and looked at INCY's pipeline. An effective oral arthritis drug in the pipeline will send this stock thru the roof if it makes it thru phase II trials. Its currently about 3 months into the phase II trial.

Recs

0
Member Avatar WakiDay (< 20) Submitted: 1/8/2010 12:27:21 PM : Outperform Start Price: $10.86 INCY Score: +251.92

GREAT drug development stock.

Recs

0
Member Avatar TMFBiologyFool (98.65) Submitted: 12/21/2009 4:15:23 PM : Underperform Start Price: $8.72 INCY Score: -350.11

$1 billion market cap is too big for the pipeline.

Recs

0
Member Avatar lonewulf47638 (43.48) Submitted: 12/18/2009 12:04:14 PM : Outperform Start Price: $8.44 INCY Score: +364.18

good news today on new drug. growth will happeen soon.

Recs

0
Member Avatar MDmomma (< 20) Submitted: 12/8/2009 11:38:58 AM : Outperform Start Price: $8.00 INCY Score: +394.53

Successful JAK2 inhibition has great potential in both hematologic and rheumatologic disease. Being an oral drug could actually be a drawback, as injectable drugs are usually covered by insurances and oral ones less so.

Recs

0
Member Avatar bklynmp3j (99.22) Submitted: 8/25/2009 12:23:31 AM : Outperform Start Price: $6.15 INCY Score: +552.15

insider buying

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement